Fatigue is defined by subjective experience and measured via patient-reported outcome (PRO) instruments. PRO tools that are MS-specific can improve understanding of MS fatigue and its impact, improving its clinical management. However, currently available PROs that assess MS-related fatigue do not meet instrument development and psychometric property requirements based on current guidelines.
The FSIQ-RMS is a novel MS-specific PRO instrument, which was developed to assess both fatigue in patients with relapsing MS and its impact on physical activity, cognitive and emotional functioning, and coping mechanisms [1]. An ongoing non-interventional prospective, longitudinal study, presented by Marion Azoulai (Carenity, France), aimed at measuring MS-related fatigue symptoms and its impact on daily life in a real-world population using a self-administered online questionnaire, including the FSIQ-RMS [2].
A total of 200 relapsing MS patients completed the 7-day assessment. The most impactful symptoms on daily functioning were fatigue and walking difficulties. Patients with lower disability rated fatigue as the most impactful symptom on daily life. A majority of patients (55%) experienced fatigue before MS diagnosis. Most patients (76%) were not currently relapsing, and these had a mean fatigue symptom domain score of 55.6, compared with 67.3 in relapsing patients. A majority of patients were not depressed (54%) and did not report a sleep disorder (71%). Heat exposure was the most common triggering factor for fatigue (82%).
In conclusion, this survey showed that fatigue occurred in most MS patients and influenced their daily functioning. The FSIQ-RMS measures fatigue symptoms and impact, which is relevant and meaningful to patients.
- Hudgens S. Value Health. 2019;22(4):453-466.
- Azoulai M, et al. A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale. ECF 28th Annual Meeting. Abstract 38.
Posted on
Previous Article
« No increased risk with IFN-β use during pregnancy Next Article
First long-term efficacy data of a BTK inhibitor »
« No increased risk with IFN-β use during pregnancy Next Article
First long-term efficacy data of a BTK inhibitor »
Table of Contents: ECF 2020
Featured articles
ECF Round-Up Articles
No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS
Defining phenotypes of MS-related cognitive impairment
First long-term efficacy data of a BTK inhibitor
Novel disease-specific scale confirms huge impact of fatigue
Progressive aerobic exercise improves fatigue
Reliable and convenient method to assess cognitive function in MS patients
Tackling unmet MS-related cognitive challenges
Real-world efficacy of ocrelizumab in MS patients
Similar demographics, clinical characteristics, and treatment patterns in German claims study
Decreased EDSS after plasma exchange in NMOSD
No support for IVIG as treatment of acute attacks in NMOSD
Related Articles
December 16, 2020
Progressive aerobic exercise improves fatigue
December 16, 2020
No increased risk with IFN-β use during pregnancy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com